Defitelio (defibrotide): Do not use for prophylaxis of veno-occlusive disease (VOD) after post-hematopoietic stem-cell transplantation (HSCT)

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Defitelio
Active substance
defibrotide
Therapeutic area (MeSH)
Hepatic Veno-Occlusive Disease
Procedure number
EMEA/H/C/004093/II/0030
Regulatory outcome
Maintenance
DHPC type
  • Lack of effect
  • Safety signal
Human ATC code
B01AX01
Dissemination date
13/06/2022

How useful was this page?

Add your rating